Quick Facts

• Therapeutic Domain: Coronary Artery Disease
• Key Action: Helps to reduce the risk of thrombotic events
• Use Context: Adjunct therapy during percutaneous coronary intervention (PCI)
• Patient Profile: For patients who have not received an oral P2Y12 inhibitor prior to the procedure

---

Kengrexal (cangrelor) is a prescription medication utilized in a hospital setting as an adjunct therapy for certain adult patients with coronary artery disease who are undergoing percutaneous coronary intervention (PCI). This procedure is used to open blocked or narrowed coronary arteries to restore blood flow to the heart muscle.

The core therapeutic benefit of Kengrexal is to help reduce the occurrence of specific thrombotic cardiovascular events during and immediately following the PCI procedure. These events include periprocedural myocardial infarction (MI, or heart attack), the need for repeat coronary revascularization (an additional procedure to restore blood flow), and stent thrombosis (clot formation within a coronary stent).

Kengrexal is reserved for patients who have not been pre-treated with an oral P2Y12 inhibitor and in whom treatment with such oral medication is either not possible or not desired in the acute care setting. It is administered via intravenous infusion for a short duration during and after the intervention.

Who Can and Cannot Use Kengrexal (Cangrelor)?

Kengrexal is approved strictly for use in adult patients (aged 18 years and older) who are undergoing Percutaneous Coronary Intervention (PCI). Eligibility is conditional: the medicine is reserved for patients who have not been pre-treated with an oral P2Y12 inhibitor prior to the procedure, or when oral therapy is not possible in the acute care setting.

---

Absolute Non-Eligibility (Contraindications)

Kengrexal is contraindicated (must not be used) in patients with the following conditions, as stated in regulatory labels:

• Significant active bleeding.
• A history of stroke or transient ischaemic attack (TIA).
• Known hypersensitivity to cangrelor or any of its components.

Population-Specific Restrictions

Population/Condition	Eligibility Status or Regulatory Caution
Pediatric Population (under 18)	Use not established; safety and efficacy data are insufficient.
Severe Renal Impairment	Use requires caution due to a reported risk of worsening renal function and bleeding events. No dose adjustment is required for any degree of renal or hepatic impairment.
Pregnancy/Lactation	In emergencies, life-sustaining therapy should not be withheld during pregnancy. During lactation, a risk to the infant cannot be excluded.

Interactions with other medicines and products

Kengrexal's official regulatory profile establishes specific interaction patterns, primarily concerning other antiplatelet agents and the drug's metabolic pathway.

Pharmacodynamic and Timing Interactions

The co-administration of Clopidogrel or Prasugrel (oral P2Y12 inhibitors) during the Kengrexal infusion is officially documented to result in the lack of the expected antiplatelet effect of the oral agent. This is due to pharmacodynamic competition at the P2Y12 receptor. Regulatory agencies mandate strict timing rules for transition: Clopidogrel (600 mg) must be given immediately after discontinuation of the Kengrexal infusion. Prasugrel (60 mg) must be given immediately after discontinuation or up to one hour before. Conversely, Ticagrelor (180 mg) may be administered at any time during or after the Kengrexal infusion.

Co-administration with other antithrombotic agents, such as heparins or GP IIb/IIIa inhibitors, is documented to increase the general risk of bleeding, a common pharmacodynamic outcome for this drug class.

Metabolic and Substance Interactions

Official labeling confirms that Kengrexal's metabolism is not dependent on CYP enzymes, and it does not inhibit major CYP isoenzymes, documenting the absence of this common pharmacokinetic interaction type. Caution is advised when Kengrexal is combined with BCRP substrates due to in vitro data suggesting transporter inhibition by a metabolite. Furthermore, due to the presence of the excipient sorbitol, Kengrexal is officially restricted in patients with hereditary fructose intolerance.

Direct Blockade of the Platelet P2Y12 Receptor

Kengrexal exerts its core action as a direct and reversible antagonist of the P2Y12 receptor on the platelet surface, competitively blocking the binding of the physiological mediator, Adenosine Diphosphate ( ADP). This molecular interaction prevents the ADP-dependent signaling that activates the platelet and ultimately dictates the resulting inhibition of platelet aggregation.

Modulation of the Intracellular Activation Cascade

The blockade of P2Y12 prevents the downstream suppression of adenylyl cyclase, thereby preserving high intracellular levels of cyclic AMP ( cAMP). This cAMP signal provides a key inhibitory feedback, which modulates the activation of the GPIIb/IIIa receptor complex—the final mechanism required for platelets to cross-link with fibrinogen and form a stable thrombus.

Dynamic Modulation through Rapid Kinetics

This drug is direct-acting, meaning it is active immediately upon administration without metabolic delay, which ensures an immediate onset of the antiaggregatory effect. Furthermore, it is quickly inactivated by endothelial endonucleotidase, resulting in a rapid reversal of platelet inhibition. The rapid onset and offset profile contributes to a predictable, transient modulation of platelet responsiveness.

How Kengrexal is Used

Kengrexal (cangrelor) is administered as a short-term, acute antiplatelet therapy exclusively within a supervised hospital environment. Its usage is strictly limited to patients undergoing percutaneous coronary intervention (PCI).

---

Administration Route and Preparation

Kengrexal has one official route of administration: intravenous (IV) infusion. The drug is supplied as a lyophilized powder for concentrate, requiring reconstitution and subsequent dilution by a healthcare professional prior to administration. The reconstitution is typically performed with Sterile Water for Injection, followed by dilution in a solution such as Normal Saline or 5% Dextrose to achieve the required concentration for infusion.

---

Standard Dosing Regimen and Duration

The standard regimen for adult patients undergoing PCI is delivered in two parts and is weight-based:

1. Initial Bolus Dose: A 30 mcg/kg IV bolus is administered rapidly, immediately before the start of the PCI procedure.
2. Maintenance Infusion: This is followed immediately by a 4 mcg/kg/min continuous IV infusion.

The treatment is short-term; the maintenance infusion must be continued for at least two hours or for the duration of the PCI procedure, whichever is longer, up to a total maximum time of four hours.

---

Usage Constraints and Population Rules

Kengrexal must be administered via a dedicated intravenous line to avoid compatibility issues with other concurrent medications. It is noted that no specific dose adjustment is required for older adults or patients with mild, moderate, or severe renal impairment, or for mild or moderate hepatic impairment. Dosing recommendations are not established for pediatric patients.

Evidence for use in Percutaneous Coronary Intervention (PCI)

Kengrexal was primarily studied for its use during Percutaneous Coronary Intervention (PCI). The research examined how the drug was evaluated for its role in addressing immediate or very short-term clotting patterns that can occur during and right after this critical procedure, which involves placing a stent to open blocked heart vessels.

Clinical research involving large patient populations was evaluated in this setting. The findings indicate patterns related to its use, and it was evaluated for its role in patterns related to acute changes in blood flow during the PCI procedure. The studies primarily focused on outcomes related to systemic or functional imbalance measured during the short-term study period.

---

Evidence for use in Acute Coronary Syndromes (ACS)

Kengrexal was also evaluated in research settings involving patients experiencing acute coronary syndromes (ACS), such as a heart attack or unstable chest pain. Studies monitored patients who received Kengrexal as part of their initial management plan for these events. The evidence contributes to understanding short-term changes during a period of temporary physiological imbalance, but the data mainly show patterns related to its use leading up to the PCI procedure itself.

---

️ Long-term studies and follow-up

Since Kengrexal is a short-acting medication, the main clinical research focused on its use during the procedure and the transition to an oral anti-clotting medication. Follow-up research examined how symptoms evolved in the observed populations for up to 30 days after the infusion stopped. However, the long-term effects of the drug itself are not fully established, and there is limited information for outcomes extending over several months or years.

---

Evidence in special populations

Clinical research explored how Kengrexal was evaluated in specific patient groups, including older adults and individuals with certain levels of kidney impairment. Data show patterns related to its use in these populations. It is important to understand that data for other groups, such as pregnancy-related populations or children, remain insufficient, and results apply only to the specific populations studied.

---

What is still uncertain about Kengrexal

This section synthesizes areas where certainty remains low. Comparative evidence is lacking between different acute anti-clotting strategies in some contexts. Additionally, because the main focus of the research was on immediate, acute outcomes, long-term patient-reported outcomes describing perceived discomfort were not the primary focus of the research. Findings were mixed in some smaller analyses, and research is ongoing to help address these evidence gaps.

Common questions about Kengrexal (FAQ)

Q: Is Kengrexal considered a 'blood thinner'?

Kengrexal is not officially categorized as a 'blood thinner,' but rather as an antithrombotic agent and P2Y12 platelet inhibitor. Its function is to prevent certain blood cells, called platelets, from clumping together to form a clot.

---

Q: Can Kengrexal affect a person's blood pressure?

Official product information indicates that changes in blood pressure, including reports of hypertension (high blood pressure) and falls in blood pressure (hypotension), have been noted in clinical trial summaries. Regulatory documents describe that a sudden fall in blood pressure requires evaluation by a healthcare professional, as it may be considered in relation to internal bleeding and cessation of the medicine.

---

Q: Is it common to feel dizzy or lightheaded after receiving Kengrexal?

While dizziness or lightheadedness are not listed among the most frequently reported side effects, some trial summaries have noted reports of a fall in blood pressure (hypotension). This drop in blood pressure is a condition that can sometimes cause feelings of dizziness or lightheadedness.

---

Q: Does Kengrexal interact with common over-the-counter pain medications like ibuprofen?

Regulatory-based drug information notes that caution is used when Kengrexal is combined with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen. Due to the way both medicines affect the body’s clotting process, their co-administration may be associated with an increased overall risk of bleeding.

---

Q: Can Kengrexal interact with certain cholesterol-lowering medicines (statins)?

Official data indicates Kengrexal is not dependent on CYP enzymes for metabolism, which limits many common drug interactions. However, a caution exists regarding potential interactions with medicines that are substrates of the BCRP transporter, which includes some statins. This interaction is noted as a possibility for one of Kengrexal's metabolites.

---

Q: What were the key clinical trials or studies that supported the approval of Kengrexal?

Kengrexal was primarily supported by a large clinical research program called the CHAMPION studies, including the CHAMPION PHOENIX trial. These studies were randomized, double-blind trials involving thousands of patients undergoing PCI and compared Kengrexal against other antiplatelet therapies.

---

Q: Why is Kengrexal given through an IV (intravenously) instead of a pill?

Kengrexal is given intravenously because it is a direct-acting agent with an immediate onset of effect, which is necessary during time-sensitive procedures like percutaneous coronary intervention (PCI). The IV route allows for highly predictable and controlled inhibition of platelets that can be quickly reversed once the infusion is stopped. The drug’s IV delivery system supports its positioning, allowing for precise control in a supervised medical environment.

---

Q: What is the purpose of stopping the Kengrexal infusion after the procedure is complete?

Kengrexal is designed to be a short-term, acute therapy used to cover the high-risk period of the PCI procedure itself. The infusion is stopped to allow the effects of the drug to quickly wear off, allowing for the transition to a longer-acting oral antiplatelet medication for continued long-term prevention.

---

Q: Is Kengrexal used for any purposes other than procedures related to coronary arteries?

Official approvals for Kengrexal focus on its use as an adjunct to percutaneous coronary intervention (PCI). While studies have been conducted on its use in patients experiencing acute coronary syndromes (ACS), the official indication is specifically linked to its role during the PCI procedure.

---

Q: Is Kengrexal considered a new medication, or has it been available for a long time?

Kengrexal, known by its active ingredient cangrelor, was first approved by the U.S. Food and Drug Administration (FDA) on June 22, 2015.

---

Q: Why is Kengrexal sometimes referred to by its brand name and sometimes by its active ingredient?

Kengrexal is the brand name given by the manufacturer, while cangrelor is the active ingredient (or generic name). Medical professionals commonly use the active ingredient name (cangrelor) for clarity and consistency across drug classes, while the brand name (Kengrexal) is used when prescribing or referencing the specific product.

How to Store and Dispose of Kengrexal (Cangrelor)

This medication is a lyophilized powder for concentrate supplied in single-use vials, and its storage rules are highly dependent on the stage of preparation.

Storage Requirements

Product Form	Required Condition
Unopened Vial (US)	Store at controlled room temperature (20 C to 25 C).
Unopened Vial (EU/UK)	No special storage conditions are required.
Reconstituted Concentrate	Must not be refrigerated.
Diluted Solution Stability	Stable for up to 24 hours in Normal Saline or up to 12 hours in 5% Dextrose Injection, stored at room temperature.

All vials must be kept out of the sight and reach of children.

---

Disposal

Any unused portion of the reconstituted solution remaining in the vial must be discarded. All unused medicinal product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste.